The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...
Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback